Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WXSH0176
- Development stage
- Phase 2
- Lead developer
- Cisen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
WXSH0176 is an orally administered small molecule Janus kinase 1 (JAK1) inhibitor developed by Chenxin Pharmaceutical. It is primarily being investigated for the treatment of ulcerative colitis. By selectively inhibiting the JAK1 isoform, the drug blocks the signal transduction of various pro-inflammatory cytokines, including interleukins and interferons, which play a critical role in the inflammatory response of the colonic mucosa. This selectivity is intended to provide a better safety profile compared to non-selective JAK inhibitors by minimizing effects on erythropoiesis and immune cell populations regulated by JAK2 and JAK3. WXSH0176 is currently in early-stage clinical development in China.
02
Targets
Beyond the preview
Go deeper on WXSH0176.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WXSH0176.